Non-Melanoma Skin Cancer

Global Non-Melanoma Skin Cancer Market: Global Market Size, Trends, Competitive, Historical & Forecast Analysis, 2019-2025

Report ID: BMRC 725 | Publish Date: Jul 2029 | Category: Lifesciences and Healthcare
Global Non-Melanoma Skin Cancer Market is expected to reach more than USD 659.7 Million by 2025 with a CAGR of 6.2% over the forecast period. Increasing prevalence of skin cancer globally is anticipated to drive the growth of Global Non-Melanoma Skin Cancer Market.

Scope of Non-Melanoma Skin Cancer Market Report:

Non-melanoma skin cancer (NMSC) is by far the most frequently diagnosed cancer around the globe. It is also one of the most common occupational diseases in Europe and its prevalence continues to increase. It affects more men than women and is more common in the elderly. It refers to the all types of cancer that occur in the skin which are not melanoma. Sometimes cells in the skin, change and no longer grow normally. These changes may lead to non-cancerous growths such as moles, dermatofibromas, warts and skin tags. But in some cases, these changes can cause non-melanoma skin cancer. It starts in round cells called basal cells and this type of cancer is called basal cell carcinoma (BCC) and makes up about 75%–80% of all skin cancers. It can also start in squamous cells of the skin and this type of cancer is called squamous cell carcinoma (SCC) and makes up about 20% of all skin cancers. Non-melanoma skin cancer treatment depends on the type, size and location of cancer. Surgery is the main treatment for non-melanoma skin cancer which involves the removal of cancerous tumour and some of the surrounding skin. Other treatments include; freezing (cryotherapy), anti-cancer creams, radiotherapy and a form of light treatment called photodynamic therapy (PDT). Global Non-Melanoma Skin Cancer Market report is segmented on the basis of drug type, application, end-user and region & country level. Based upon drug type, global non-melanoma skin cancer market is classified into radiation therapy, photodynamic therapy and chemotherapy. Radiation therapy is further sub-divided into electronic brachytherapy, external beam radiation therapy and superficial radiation therapy. Based upon application, global non-melanoma skin cancer market is divided into basal cell carcinoma, T-cell lymphoma, squamous cell carcinoma and others. Based on end-user, the non-melanoma skin cancer market is classified into hospitals, specialty clinics and ambulatory surgical centers. The regions covered in this Global Non-Melanoma Skin Cancer Market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, the market of non-melanoma skin cancer is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, Middle East Asia (UAE, Saudi Arabia, Egypt) GCC, Africa, etc. Key Players for Global Non-Melanoma Skin Cancer Market Report- Some major key players for Global Non-Melanoma Skin Cancer Market are Almirall S.A., Novartis AG, Mylan NV, Boehringer Ingelheim GmbH, Sensus Healthcare, iCAD, Inc., Accuray, Inc., Bristol-Myers Squibb Company, Merck & Co., Inc., Eli Lilly and Company, Elekta AB, F. Hoffmann-La Roche Ltd., Sun Pharmaceutical Industries Ltd., Varian Medical Systems, Inc., Ion Beam Applications SA and others. Increasing Prevalence of Skin Cancer Globally, Drives the Growth of Global Non-Melanoma Skin Cancer Market- The major factors driving the growth of global non-melanoma skin cancer market are increasing prevalence of skin cancer and growing awareness regarding its treatment. For example; As per WHO; Currently, between 2 and 3 million non-melanoma skin cancers and 132,000 melanoma skin cancers occur globally each year. According to Skin Cancer Foundation Statistics, one in every five Americans will develop skin cancer in their lifetime. And as per World Cancer Research Fund International; Non-melanoma skin cancer is the 5th most commonly occurring cancer in men and women, with over 1 million diagnosed worldwide in 2018, although this is likely to be an underestimate. In addition, increasing government funding for research activities and increasing number of clinical trials are also supplementing the growth of the global non-melanoma skin cancer treatment market. Furthermore, improving healthcare infrastructure is also supplementing the growth of the market. However, side-effects of radiation therapy may hamper the global non-melanoma skin cancer treatment market during the forecast period. In spite of that, increasing advancements in the field of innovative products can provide various opportunities for the further growth of the market. Geographically, this report split global into several key Regions, revenue (Million USD) The geography (North America, Europe, Asia-Pacific, Latin America and Middle East & Africa) focusing on key countries in each region. It also covers market drivers, restraints, opportunities, challenges, and key issues in Global Non-Melanoma Skin Cancer Market. Key Benefits for Non-Melanoma Skin Cancer Market Reports • Global market report covers in-depth historical and forecast analysis. • Global market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Competitive Analysis, Regional and Country Level. • Global market report helps to identify opportunities in market place. • Global market report covers extensive analysis of emerging trends and competitive landscape.

Non-Melanoma Skin Cancer Market Segmentation:

By Drug Type: • Radiation Therapy o Electronic Brachytherapy o External Beam Radiation Therapy o Superficial Radiation Therapy • Photodynamic Therapy • Chemotherapy By Application: • Basal Cell Carcinoma • T-Cell Lymphoma • Squamous Cell Carcinoma • Others By End-User: • Hospitals • Specialty Clinics • Ambulatory Surgical Centers By Region • North America o U.S. o Canada o Mexico • Europe o UK o France o Germany o Russia o Rest of Europe • Asia-Pacific o China o South Korea o India o Japan o Rest of Asia-Pacific • LAMEA o Latin America o Middle East o Africa North America is Expected to Dominate the Global Non-Melanoma Skin Cancer Market- The global non-melanoma skin cancer market is segmented into North America, Europe, Asia-Pacific, Latin America and Middle East & Africa. North America is expected to dominate the global non-melanoma skin cancer market within the forecast period attributed to the highly developed healthcare infrastructure and increasing cases of non-melanoma skin cancer in this region. For example; As per the American Academy of Dermatology; It is estimated that approximately 9,500 people in the U.S. are diagnosed with skin cancer every day. Research estimates that non-melanoma skin cancer, including basal cell carcinoma and squamous cell carcinoma, affects more than 3 million Americans a year. In addition, increasing number of cancer treatment centers and presence of leading market players in this region are also supplementing the market growth. Europe is projected to capture the second largest share of global non-melanoma skin cancer market owing to the increasing prevalence of occupational non-melanoma skin cancer in this region. In the European Union, more than 14.5 million workers are regularly exposed to solar UV radiation for more than 75% of their daily working hours. Occupational skin diseases, which also includes contact dermatitis, are estimated to lead to costs far beyond €5 billion annually in the EU alone. Asia Pacific is anticipated to witness a significant growth in global non-melanoma skin cancer market owing to the increasing healthcare spending, improving healthcare infrastructure and increasing research and development for new and more effective treatments in this region. Non-Melanoma Skin Cancer Market Key Players: • Almirall S.A. • Novartis AG • Mylan NV • Boehringer Ingelheim GmbH • Sensus Healthcare • iCAD, Inc. • Accuray, Inc. • Bristol-Myers Squibb Company • Merck & Co., Inc. • Eli Lilly and Company • Others This comprehensive report will provide: • Enhance your strategic decision making • Assist with your research, presentations and business plans • Show which emerging market opportunities to focus on • Increase your industry knowledge • Keep you up-to-date with crucial market developments • Allow you to develop informed growth strategies • Build your technical insight • Illustrate trends to exploit • Strengthen your analysis of competitors • Provide risk analysis, helping you avoid the pitfalls other companies could make • Ultimately, help you to maximize profitability for your company. Our Market Research Solution Provides You Answer to Below Mentioned Question: • Which are the driving factors responsible for the growth of market? • Which are the roadblock factors of this market? • What are the new opportunities, by which market will grow in coming years? • What are the trends of this market? • Which are main factors responsible for new product launch? • How big is the global & regional market in terms of revenue, sales and production? • How far will the market grow in forecast period in terms of revenue, sales and production? • Which region is dominating the global market and what are the market shares of each region in the overall market in 2017? • How will each segment grow over the forecast period and how much revenue will these segment account for in 2025? • Which region has more opportunities?
Interested in this report?
Get your sample now!
Table of Content

1. Chapter - Report Methodology
1.1. Research Process 
1.2. Primary Research 
1.3. Secondary Research
1.4. Market Size Estimates
1.5. Data Triangulation
1.6. Forecast Model 
1.7. USP’s of Report 
1.8. Report Description 
2. Chapter – Global Non-Melanoma Skin Cancer Market Overview: Qualitative Analysis
2.1. Market Introduction
2.2. Executive Summary 
2.3. Global Non-Melanoma Skin Cancer Market Classification
2.4. Market Drivers
2.5. Market Restraints
2.6. Market Opportunity
2.7. Non-Melanoma Skin Cancer Market: Trends
2.8. Porter’s Five Forces Analysis
2.8.1. Bargaining Power of Suppliers
2.8.2. Bargaining Power of Consumers
2.8.3. Threat of New Entrants
2.8.4. Threat of Substitute Product and Services
2.8.5. Competitive Rivalry within the Industry
2.9. Market Attractiveness Analysis 
2.9.1. Market Attractiveness Analysis by Segmentation 
2.9.2. Market Attractiveness Analysis by Region 
3. Chapter - Global Non-Melanoma Skin Cancer Market Overview: Quantitative Analysis
3.1. Global Non-Melanoma Skin Cancer Market Revenue (USD Million), Market Share (%) and Growth Rate (%), 2014- 2025
3.2. Global Non-Melanoma Skin Cancer Market Revenue Market Share (%), 2014- 2025
3.3. Global Non-Melanoma Skin Cancer Market Sales (Number of Units), Market Share (%) and Growth Rate (%), 2014- 2025
3.4. Global Non-Melanoma Skin Cancer Market Sales Market Share (%), 2014- 2025
4. Chapter – Global Non-Melanoma Skin Cancer Market Analysis: By Drug Type
5. Chapter – Global Non-Melanoma Skin Cancer Market Analysis: By Application
6. Chapter – Global Non-Melanoma Skin Cancer Market Analysis: By End-User
7. Chapter - Global Non-Melanoma Skin Cancer Market Analysis: By Manufacturer 
7.1. Global Non-Melanoma Skin Cancer Market Revenue (USD Million), by Manufacturer, 2014 - 2025
7.2. Global Non-Melanoma Skin Cancer Market Share (%), by Manufacturer, 2018
7.3. Global Non-Melanoma Skin Cancer Market Sales (Number of Units), by Manufacturer, 2014 - 2025
7.4. Global Non-Melanoma Skin Cancer Market Share (%), by Manufacturer, 2018
7.5. Global Non-Melanoma Skin Cancer Market Price (USD/Unit), by Manufacturer, 2014 - 2025
7.6. Global Non-Melanoma Skin Cancer Market Revenue Growth Rate (%), by Manufacturer, 2014 – 2025
7.7. Merger & Acquisition
7.8. Collaborations and Partnership
7.9. New Product Launch
8. Chapter –Non-Melanoma Skin Cancer Market: Regional Analysis
8.1. North America
8.1.1. North America Non-Melanoma Skin Cancer Market Revenue (USD Million) and Growth Rate (%), 2014 – 2025.
8.1.2. North America Non-Melanoma Skin Cancer Market Revenue (USD Million) By Country, 2014 – 2025.
8.1.3. North America Non-Melanoma Skin Cancer Revenue Market Share (%) By Country, 2014 – 2025.
8.1.4. North America Non-Melanoma Skin Cancer Market Revenue (USD Million) and Growth Rate, By Market Segmentation, 2014 – 2025.
8.1.5. North America Non-Melanoma Skin Cancer Market Revenue (USD Million), Market Share (%) and Growth Rate, By Market Segmentation, 2014 – 2025.
8.1.6. North America Non-Melanoma Skin Cancer Market Sales (Number of Units) and Growth Rate (%), 2014 – 2025.
8.1.7. North America Non-Melanoma Skin Cancer Market Sales (Number of Units) By Country, 2014 – 2025.
8.1.8. North America Non-Melanoma Skin Cancer Sales Market Share (%) By Country, 2014 – 2025.
8.1.9. North America Non-Melanoma Skin Cancer Market Sales (Number of Units) and Growth Rate, By Market Segmentation, 2014 – 2025.
8.1.10. North America Non-Melanoma Skin Cancer Market Sales (Number of Units), Market Share (%) and Growth Rate, By Market Segmentation, 2014 – 2025.
8.2. Europe
8.3. Asia Pacific
8.4. Latin America
8.5. Middle East & Africa
9. Chapter - Company Profiles
9.1. Almirall S.A.
9.1.1. Overview
9.1.2. Financials
9.1.3. Product portfolio
9.1.4. Non-Melanoma Skin Cancer Market Revenue (USD Million) and Market Share (%), 2014 - 2018
9.1.5. Non-Melanoma Skin Cancer Sales Market Share (%), 2014 - 2018
9.1.6. Business strategy
9.1.7. Recent developments
9.2. Novartis AG
9.3. Mylan NV
9.4. Boehringer Ingelheim GmbH
9.5. Sensus Healthcare
9.6. iCAD, Inc.
9.7. Accuray, Inc.
9.8. Bristol-Myers Squibb Company
9.9. Merck & Co., Inc.
9.10. Eli Lilly and Company
9.11. Elekta AB
9.12. F. Hoffmann-La Roche Ltd.
9.13. Sun Pharmaceutical Industries Ltd.
9.14. Varian Medical Systems, Inc.
9.15. Ion Beam Applications SA 
9.16. Others
10. Chapter – Market Research and Findings